Eisai and Biogen Report Long-Term Lecanemab Outcomes in Alzheimer’s

Share on Social Media

Five-year lecanemab clinical outcomes and disease progression findings in early Alzheimer's disease
Image: Pixels

Five-year lecanemab data from Clarity AD show sustained differences in Alzheimer’s disease progression, low-tau subgroup outcomes and declining ARIA-E incidence.

Written By: Anshu Gupta, PharmD

Reviewed By: Pharmacally Editorial Team

Eisai and Biogen announced new five-year findings from the Clarity AD long-term extension (LTE) study on November 16, 2026. Presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, the findings evaluated long-term outcomes associated with continuous treatment with lecanemab-irmb (LEQEMBI®) in patients with early Alzheimer’s disease (AD).

Lecanemab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody directed primarily against aggregated soluble amyloid-beta (Aβ) protofibrils, while also targeting insoluble forms of Aβ.

The global Phase 3 Clarity AD core study was a randomised, double-blind, placebo-controlled trial involving 1,795 patients with early AD. Participants received either lecanemab 10 mg/kg intravenously every two weeks (898 patients) or placebo (897 patients). Of those who completed the 18-month core study, 95% chose to enter the subsequent LTE. A total of 351 patients received five years of continuous lecanemab treatment across the core study and extension.

Clinical Outcomes and Disease-Stage Progression

The five-year analysis assessed clinical changes using the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a measure of cognitive and functional impairment in AD. Outcomes among patients receiving continuous lecanemab were compared with disease-progression data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and BioFINDER natural-history studies.

At three, four and five years, the differences in mean CDR-SB change from baseline compared with ADNI were −1.00, −1.78 and −2.05 points, respectively. Against BioFINDER, the corresponding differences were −1.42, −2.24 and −2.54 points. These increasing differences indicate sustained separation in clinical decline between the continuously treated population and the external comparison datasets.

The analysis also reported a 36% reduction in the relative risk of progression to the next disease stage compared with ADNI. By five years, 61.9% of lecanemab-treated patients had progressed from mild cognitive impairment (MCI) to mild AD dementia or from mild to moderate AD dementia, compared with 77.5% in ADNI.

For progression from early AD to moderate or severe dementia, the relative risk was 49% lower compared with ADNI. Progression to these stages was reported in 31% of lecanemab-treated patients, compared with 48.7% in the external dataset.

Disease-stage progression was assessed using CDR-SB score ranges rather than the global Clinical Dementia Rating (CDR), allowing more detailed assessment of disease-stage transitions.

Outcomes in Patients with Low Baseline Tau

The Clarity AD programme included an optional tau positron emission tomography (PET) substudy to identify patients with low levels of tau accumulation in the brain, representing an earlier biological stage of AD.

After five years of lecanemab treatment, 66% of patients in the low-tau group showed no decline, including stable or improved CDR-SB scores, while 62% demonstrated improvement.

On the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 14 (ADAS-Cog14), 55% showed no decline and 52% demonstrated improvement. On the Alzheimer’s Disease Cooperative Study–Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS MCI-ADL), 69% showed no decline, while 62% demonstrated improvement.

These findings provide additional information on long-term cognitive and functional outcomes among patients who started treatment at an earlier biological stage. However, the results represent a subgroup analysis and should not be generalised to the entire study population.

Five-Year Safety Findings

No new safety findings were observed during five years of continuous lecanemab treatment. Amyloid-related imaging abnormalities with edema or effusion (ARIA-E) occurred most frequently during the first six months of treatment.

Across successive 12-month treatment intervals, ARIA-E incidence was 13.5% during the first year, followed by 3.6% in the second year, 1.1% in the third year, 1.3% in the fourth year and 0.6% in the fifth year. The corresponding incidence in the placebo group was 1.7% over the 18-month core study.

Clinical Interpretation

The five-year findings extend observations from the original Clarity AD study and provide further information on outcomes associated with continued lecanemab treatment. The increasing differences in CDR-SB scores against ADNI and BioFINDER suggest sustained separation in clinical decline over time.

The low-tau subgroup findings highlight the potential importance of investigating treatment during earlier biological stages of AD. However, the reported percentages should be interpreted within the context of the subgroup analysis.

Importantly, the five-year efficacy comparisons were made against external natural-history datasets rather than a concurrent randomised placebo group followed for the entire five-year period. Differences in patient characteristics, baseline disease severity and study methodology may influence these comparisons. Furthermore, the five-year findings were derived from 351 patients who received continuous treatment, a subset of the original 1,795 participants. The size and characteristics of this long-term treatment population should therefore be considered when interpreting the findings. The available announcement does not establish how much of the difference in patient numbers resulted from staggered extension enrolment versus treatment discontinuation.

Similarly, declining ARIA-E incidence across successive treatment intervals represents a relevant long-term safety observation but does not establish the elimination of treatment-related risks or remove the need for continued monitoring.

Eisai leads global development and regulatory submissions for lecanemab, while Eisai and Biogen jointly com

References

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026, Biogen and Eisai, November 16, 2026.

A Study to Confirm Safety and Efficacy of Lecanemab in Participants with Early Alzheimer’s Disease (Clarity AD), ClinicalTrials.gov ID NCT03887455

PharmD Intern

About the Writer

Anshu Gupta (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, regulatory affairs, and medical writing. She has presented research at academic conferences and completed certifications in Good Clinical Practice (GCP), ICH-GCP, and drug safety. Passionate about clinical trials and evidence-based medicine, she is committed to translating scientific evidence into accurate, reliable, and accessible healthcare content.


Share on Social Media
Scroll to Top